Tim Eisen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tim Eisen has a total of 307 co-authors. Here are the top co-authors by number of shared publications:
- Grant D. Stewart
Department of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
16 shared publications - Lisa Pickering
The Royal Marsden Hospital NHS Foundation Trust
16 shared publications Andrea Carmack
15 shared publications- Andrew B. Nixon
Department of Medicine, Duke University Medical Center, Durham, USA
15 shared publications - Andrew J. Armstrong
Division of Medical Oncology, Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, USA
15 shared publications Andrew Protheroe
15 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
A P21+/MCM2− Subpopulation of CD105+ Cells Predicts Favourable Outcome in Renal Cell Carcinoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
A P21+/MCM2− Subpopulation of CD105+ Cells Predicts Favourable Outcome in Renal Cell Carcinoma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
Validation of P21+/MCM2− cell content as a prognostic biomarker across high-risk LS SORCE and pan-risk LS Scottish cohorts. In both high-risk patients and the pan-risk cohort, a 2% threshold stratifies relapse risk, with higher proportions associated with favorable survival outcomes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
Validation of P21+/MCM2− cell content as a prognostic biomarker across high-risk LS SORCE and pan-risk LS Scottish cohorts. In both high-risk patients and the pan-risk cohort, a 2% threshold stratifies relapse risk, with higher proportions associated with favorable survival outcomes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
Current clinical tools for predicting relapse and guiding adjuvant therapy in clear cell renal cell carcinoma (ccRCC) lack precision, especially in intermediate-risk disease. This study evaluated whether a nonproliferative tumor cell phenotype, P21 (CDKN1A inhibitor)–positive and MCM2 (DNA replication protein)–negative (P21+/MCM2−), could serve as a robust biomarker to improve prognostic stratification and guide postnephrectomy treatment decisions. We used multiplex immunofluorescence and Artificial Intelligence–based image analysis on nephrectomy specimens from three independent ccRCC cohorts: UK arm of the SORCE trial (n = 382), Korean (n = 71), and Scottish (n = 88). An optimal 2% cutoff for P21+/MCM2− cells was determined using X-tile software. Additional analyses assessed endoglin/CD105 coexpression, paired primary–metastatic samples (n = 41), and associations with adjuvant sorafenib therapy. In two intermediate-risk ccRCC cohorts (SORCE, n = 63; Korean, n = 71), patients with >2% P21+/MCM2− cells had significantly longer time to relapse [HR = 0.17; 95% confidence interval (CI), 0.06–0.54; HR = 0.27; 95% CI, 0.10–0.72]. Prognostic value was confirmed in high-risk (SORCE, HR = 0.43; 95% CI, 0.19–0.99) and all-risk (Scottish, HR = 0.37; 95% CI, 0.14–0.98) cohorts. Notably, patients with high P21+/MCM2− levels on placebo fared better than those receiving adjuvant TKI therapy (HR = 0.29; 95% CI, 0.16–0.50). In 41 paired samples, 85% showed higher P21+/MCM2− abundance in metastases than in primary tumors. As a conclusion, P21+/MCM2− cell count is a robust biomarker that refines relapse risk stratification in ccRCC and identifies patients who may not benefit from adjuvant tyrosine kinase inhibitor (TKI) therapy. High levels of these nonproliferative, senescent-like cells suggest tumor dormancy and a more favorable outcome without treatment.Significance:After surgery for clear cell renal cell carcinoma, relapse risk and benefit from adjuvant therapy remain uncertain. We identify a distinct P21+/MCM2− tumor phenotype, nonproliferative and senescent-like, linked to favorable outcomes. Across three cohorts, >2% of these cells reduced relapse risk, but benefit was lost with adjuvant TKIs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
Current clinical tools for predicting relapse and guiding adjuvant therapy in clear cell renal cell carcinoma (ccRCC) lack precision, especially in intermediate-risk disease. This study evaluated whether a nonproliferative tumor cell phenotype, P21 (CDKN1A inhibitor)–positive and MCM2 (DNA replication protein)–negative (P21+/MCM2−), could serve as a robust biomarker to improve prognostic stratification and guide postnephrectomy treatment decisions. We used multiplex immunofluorescence and Artificial Intelligence–based image analysis on nephrectomy specimens from three independent ccRCC cohorts: UK arm of the SORCE trial (n = 382), Korean (n = 71), and Scottish (n = 88). An optimal 2% cutoff for P21+/MCM2− cells was determined using X-tile software. Additional analyses assessed endoglin/CD105 coexpression, paired primary–metastatic samples (n = 41), and associations with adjuvant sorafenib therapy. In two intermediate-risk ccRCC cohorts (SORCE, n = 63; Korean, n = 71), patients with >2% P21+/MCM2− cells had significantly longer time to relapse [HR = 0.17; 95% confidence interval (CI), 0.06–0.54; HR = 0.27; 95% CI, 0.10–0.72]. Prognostic value was confirmed in high-risk (SORCE, HR = 0.43; 95% CI, 0.19–0.99) and all-risk (Scottish, HR = 0.37; 95% CI, 0.14–0.98) cohorts. Notably, patients with high P21+/MCM2− levels on placebo fared better than those receiving adjuvant TKI therapy (HR = 0.29; 95% CI, 0.16–0.50). In 41 paired samples, 85% showed higher P21+/MCM2− abundance in metastases than in primary tumors. As a conclusion, P21+/MCM2− cell count is a robust biomarker that refines relapse risk stratification in ccRCC and identifies patients who may not benefit from adjuvant tyrosine kinase inhibitor (TKI) therapy. High levels of these nonproliferative, senescent-like cells suggest tumor dormancy and a more favorable outcome without treatment.Significance:After surgery for clear cell renal cell carcinoma, relapse risk and benefit from adjuvant therapy remain uncertain. We identify a distinct P21+/MCM2− tumor phenotype, nonproliferative and senescent-like, linked to favorable outcomes. Across three cohorts, >2% of these cells reduced relapse risk, but benefit was lost with adjuvant TKIs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
Stratification by P21+/MCM2− status identifies differential responses to sorafenib in intermediate- and high-risk ccRCC. In patients with ≤2% P21+/MCM2− cells, no significant benefit from sorafenib was observed (left). In contrast, patients with >2% of these cells had significantly worse outcomes when treated with sorafenib compared with placebo (right; P < 0.001).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
Stratification by P21+/MCM2− status identifies differential responses to sorafenib in intermediate- and high-risk ccRCC. In patients with ≤2% P21+/MCM2− cells, no significant benefit from sorafenib was observed (left). In contrast, patients with >2% of these cells had significantly worse outcomes when treated with sorafenib compared with placebo (right; P < 0.001).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
P21+/MCM2− cell content improves risk stratification in intermediate-risk ccRCC. Kaplan–Meier survival analysis in the SORCE training cohort (n = 63) shows that patients with ≤2% P21+/MCM2− cells experienced significantly higher relapse rates than those with >2% (P < 0.001) within 142 months. In contrast, stratification by the raw LS (LS 3–5) demonstrated a trend that was not statistically significant (P = 0.21). Box-and-whisker plots reveal overlapping distributions of P21+/MCM2− cell percentages across LS subgroups. In the Korean validation cohort (n = 71), the same 2% threshold also significantly stratified outcomes (P = 0.005) within 195 months.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
P21+/MCM2− cell content improves risk stratification in intermediate-risk ccRCC. Kaplan–Meier survival analysis in the SORCE training cohort (n = 63) shows that patients with ≤2% P21+/MCM2− cells experienced significantly higher relapse rates than those with >2% (P < 0.001) within 142 months. In contrast, stratification by the raw LS (LS 3–5) demonstrated a trend that was not statistically significant (P = 0.21). Box-and-whisker plots reveal overlapping distributions of P21+/MCM2− cell percentages across LS subgroups. In the Korean validation cohort (n = 71), the same 2% threshold also significantly stratified outcomes (P = 0.005) within 195 months.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
Clinicopathologic characteristics of patients with primary disease only, across the SORCE, Korean, and Scottish cohorts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
Clinicopathologic characteristics of patients with primary disease only, across the SORCE, Korean, and Scottish cohorts.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
Comparison of prognostic model discrimination with and without the P21+/MCM2− biomarker
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
Comparison of prognostic model discrimination with and without the P21+/MCM2− biomarker
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
IHC detection of P21, MCM2, P16, and Lamin B1 (top) shows differential expression of cell-cycle arrest and proliferation markers in ccRCC tissue. mIF (bottom) reveals single-cell colocalization of P21 (yellow), MCM2 (green), and CD105 (red), with DAPI marking nuclei (gray).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
IHC detection of P21, MCM2, P16, and Lamin B1 (top) shows differential expression of cell-cycle arrest and proliferation markers in ccRCC tissue. mIF (bottom) reveals single-cell colocalization of P21 (yellow), MCM2 (green), and CD105 (red), with DAPI marking nuclei (gray).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
Higher P21+/MCM2− cell percentage in metastatic ccRCC. Multiplex imaging shows greater P21+/MCM2− expression in metastatic vs. primary tumors. In 35 of 41 patients, HALO AI–based quantification confirmed elevated percentages of P21+/MCM2− at metastatic sites.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
Higher P21+/MCM2− cell percentage in metastatic ccRCC. Multiplex imaging shows greater P21+/MCM2− expression in metastatic vs. primary tumors. In 35 of 41 patients, HALO AI–based quantification confirmed elevated percentages of P21+/MCM2− at metastatic sites.
- Open Access
- 1 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (5) , 1061-1070
Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
Current clinical tools for predicting relapse and guiding adjuvant therapy in clear cell renal cell carcinoma (ccRCC) lack precision, especially in intermediate-risk disease. This study evaluated whether a nonproliferative tumor cell phenotype, P21 (CDKN1A inhibitor)–positive and MCM2 (DNA replication protein)–negative (P21+/MCM2−), could serve as a robust biomarker to improve prognostic stratification and guide postnephrectomy treatment decisions. We used multiplex immunofluorescence and Artificial Intelligence–based image analysis on nephrectomy specimens from three independent ccRCC cohorts: UK arm of the SORCE trial (n = 382), Korean (n = 71), and Scottish (n = 88). An optimal 2% cutoff for P21+/MCM2− cells was determined using X-tile software. Additional analyses assessed endoglin/CD105 coexpression, paired primary–metastatic samples (n = 41), and associations with adjuvant sorafenib therapy. In two intermediate-risk ccRCC cohorts (SORCE, n = 63; Korean, n = 71), patients with >2% P21+/MCM2− cells had significantly longer time to relapse [HR = 0.17; 95% confidence interval (CI), 0.06–0.54; HR = 0.27; 95% CI, 0.10–0.72]. Prognostic value was confirmed in high-risk (SORCE, HR = 0.43; 95% CI, 0.19–0.99) and all-risk (Scottish, HR = 0.37; 95% CI, 0.14–0.98) cohorts. Notably, patients with high P21+/MCM2− levels on placebo fared better than those receiving adjuvant TKI therapy (HR = 0.29; 95% CI, 0.16–0.50). In 41 paired samples, 85% showed higher P21+/MCM2− abundance in metastases than in primary tumors. As a conclusion, P21+/MCM2− cell count is a robust biomarker that refines relapse risk stratification in ccRCC and identifies patients who may not benefit from adjuvant tyrosine kinase inhibitor (TKI) therapy. High levels of these nonproliferative, senescent-like cells suggest tumor dormancy and a more favorable outcome without treatment. Significance: After surgery for clear cell renal cell carcinoma, relapse risk and benefit from adjuvant therapy remain uncertain. We identify a distinct P21+/MCM2− tumor phenotype, nonproliferative and senescent-like, linked to favorable outcomes. Across three cohorts, >2% of these cells reduced relapse risk, but benefit was lost with adjuvant TKIs.
- 1 May 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (5) , 1061-1070
Open AccessMultiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor–Resistant Patients in Clear Cell Renal Cell Carcinoma
Current clinical tools for predicting relapse and guiding adjuvant therapy in clear cell renal cell carcinoma (ccRCC) lack precision, especially in intermediate-risk disease. This study evaluated whether a nonproliferative tumor cell phenotype, P21 (CDKN1A inhibitor)–positive and MCM2 (DNA replication protein)–negative (P21+/MCM2−), could serve as a robust biomarker to improve prognostic stratification and guide postnephrectomy treatment decisions. We used multiplex immunofluorescence and Artificial Intelligence–based image analysis on nephrectomy specimens from three independent ccRCC cohorts: UK arm of the SORCE trial (n = 382), Korean (n = 71), and Scottish (n = 88). An optimal 2% cutoff for P21+/MCM2− cells was determined using X-tile software. Additional analyses assessed endoglin/CD105 coexpression, paired primary–metastatic samples (n = 41), and associations with adjuvant sorafenib therapy. In two intermediate-risk ccRCC cohorts (SORCE, n = 63; Korean, n = 71), patients with >2% P21+/MCM2− cells had significantly longer time to relapse [HR = 0.17; 95% confidence interval (CI), 0.06–0.54; HR = 0.27; 95% CI, 0.10–0.72]. Prognostic value was confirmed in high-risk (SORCE, HR = 0.43; 95% CI, 0.19–0.99) and all-risk (Scottish, HR = 0.37; 95% CI, 0.14–0.98) cohorts. Notably, patients with high P21+/MCM2− levels on placebo fared better than those receiving adjuvant TKI therapy (HR = 0.29; 95% CI, 0.16–0.50). In 41 paired samples, 85% showed higher P21+/MCM2− abundance in metastases than in primary tumors. As a conclusion, P21+/MCM2− cell count is a robust biomarker that refines relapse risk stratification in ccRCC and identifies patients who may not benefit from adjuvant tyrosine kinase inhibitor (TKI) therapy. High levels of these nonproliferative, senescent-like cells suggest tumor dormancy and a more favorable outcome without treatment. Significance: After surgery for clear cell renal cell carcinoma, relapse risk and benefit from adjuvant therapy remain uncertain. We identify a distinct P21+/MCM2− tumor phenotype, nonproliferative and senescent-like, linked to favorable outcomes. Across three cohorts, >2% of these cells reduced relapse risk, but benefit was lost with adjuvant TKIs.